13th AACR-JCA Joint Conference
From Cancer Discovery Science to Therapeutic Innovation
February 1-5, 2025 | Maui, HI

AACR American Association for Cancer Research
JCA 日本癌学会 JAPANESE CANCER ASSOCIATION
2409026E

Abstracts to be Presented as Poster Presentations

Poster Session C
Tuesday, February 4, 5:30-7:30 p.m.
Mondarchy 5-7

New Treatment Modalities

C01 PMR-116, a second generation RNA Polymerase I inhibitor. Luc Furic. Peter MacCallum Cancer Centre, Melbourne, Australia.

C02 Intraoperative optical imaging with a new tumor-targeting probe improves the identification of positive margins. Tohru Yamada. University of Illinois at Chicago, Chicago, IL, United States.

C03 Prognostic significance of TROP2 expression and its correlation with HER2 expression in Gynecologic Carcinosarcoma. Rui Kitadai. National Cancer Center Hospital, Tokyo, Japan.

C04 Antioxidative, anti-androgenic, and inhibitory activities of ethanolic extract of Annona muricata leaf on sex hormones-induced benign prostate hyperplasia through in vivo and in silico studies. Victor U. Chigozie. David Umahi Federal University of Health Sciences, Ohaozara, Nigeria.

C05 Effects of bortezomib treatment on protein dynamics in multiple myeloma: degradation and synthesis patterns. Lina Y. Alhourani. University of Alberta, Edmonton, AB, Canada.

C06 Therapeutic potential of GRB2 inhibitors to expose DNA replication-repair venerability of cancer cells for immune destruction. Zamal Ahmed. MD Anderson Cancer Center, Houston, TX, United States.

C07 Intranasal delivery of PDGFRA-targeted nanotherapeutics for the treatment of pediatric high-grade glioma. Kentaro Mineji. University of Alabama at Birmingham, Birmingham, AL, United States.

C08 Clinical and Technical Aspects of Circulating Tumor DNA as a Predictive Marker for New Therapeutic Approaches in Locally Advanced Rectal Cancer. Klara Vokacova. Institute of Experimental Medicine CAS, Prague, Czech Republic.

C09 TLK1 suppression potentiates the anticancer effect of deep UV irradiation. Toshio Kokuryo. Nagoya University Graduate School of Medicine, Nagoya, Japan.

C10 Application of cellulose nanofiber-based extracellular vesicle sheets to novel biomarker for ovarian cancer. Yukari Nagao. Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

13th AACR-JCA Joint Conference
From Cancer Discovery Science to Therapeutic Innovation
February 1-5, 2025 | Maui, HI

AACR American Association for Cancer Research
JCA 日本癌学会 JAPANESE CANCER ASSOCIATION

2409026E

C11 A precision nanoformulation for cancer treatment using pH-sensitive coatings to deliver ER stress inducers and microRNA. Yu-Li Lo. National Yang Ming Chiao Tung University, Taipei, Taiwan (Greater China).

C12 Pharmacological activation of NF-κB as a strategy to sensitize HPV-associated head and neck cancer to radiation therapy. Aditi Kothari. University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

C13 Fluorescence-Guided Neurosurgical Oncology: Evolution, Ergonomics, Technical Advances, and Clinical Applications. Barnabas Obeng-Gyasi. Indiana University School of Medicine, Indianapolis, IN, United States.

C14 RK-582, a tankyrase poly(ADP-ribose) polymerase inhibitor, attacks colorectal cancer cells with short-type APC mutations and high β-catenin expression. Hiroyuki Seimiya. Japanese Foundation for Cancer Research, Tokyo, Japan.

C16 Novel quantification method for nucleic acid medicine using dual hybridization assay with πcode micro disc and TNA-modified probes. Kiyomitsu Kuwahara. Nagoya University Graduate School of Medicine, Nagoya, Japan.

C17 Targeting the AR co-activator CBP/p300 in metastatic castration-resistant prostate cancer (mCRPC). Ananya Dutta. Duke University, Durham, NC, United States.

C18 Targeting menin mutants with a new generation of small molecule inhibitors to overcome resistance in leukemia patients. Jolanta Grembecka. University of Michigan, Ann Arbor, MI, United States.

C19 Development of small molecule inhibitors of the Polycomb Repressive Complex 1 as a novel anti-leukemia therapy. Tomasz Cierpicki. University of Michigan, Ann Arbor, MI, United States.

C20 RAD52 inhibition induces DNA damage by accumulating R-loops in diffuse midline glioma. Eita Uchida. Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, United States.

C21 Proposal of a novel method for producing bispecific antibodies using cell fusion for immunotherapy of solid tumors. Akane Oyama. Osaka Metropolitan University, Osaka, Japan.

C22 SUMOylation inhibition boosts CAR-T cell efficacy in Burkitt's lymphoma. Seiji Yano. Kanazawa University, Kanazawa, Japan.

C23 Targeting HER2 with antibody-drug conjugates for NSCLC driven by NRG1 fusions. Igor Odintsov. Brigham and Women's Hospital, Boston, MA, United States.

C24 Isobutyl-deoxynyboquinone (IB-DNQ) in Combination with ATR Inhibitors is a Novel Strategy to Combat Recalcitrant Non-Small Cell Lung Cancers. Jarrett Smith. Indiana Univeristy School of Medicine, Indianapolis, IN, United States.

13th AACR-JCA Joint Conference
From Cancer Discovery Science to Therapeutic Innovation
February 1-5, 2025 | Maui, HI

AACR American Association for Cancer Research
JCA 日本癌学会 JAPANESE CANCER ASSOCIATION
2409026E

C25 The Doublecortin like kinase 1 (DCLK1) interactome reveals novel mechanism for cancer progression. Annalisa L.E. Carli. Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.

C26 The multi-kinase inhibitor tinengotinib as a novel therapy for advanced prostate cancer. Brandon Hernandez. Duke University School of Medicine, Durham, NC, United States.

C27 A molecular glue RBM39-degrader induces synthetic lethality in cancer cells with homologous recombination repair deficiency. Shinji Kohsaka. National Cancer Center Research Institute, Tokyo, Japan.

C28 Understanding the function and inhibiting cancer-driving H3K36 methyltransferazes. Lukasz Jaremko. KAUST, Thuwal, Saudi Arabia.

C29 Novel aneuploidy-associated therapeutic targets for squamous cell carcinoma. Nadja Zhakula-Kostadinova. Columbia University, New York, NY, United States.

C30 Exploiting metabolic vulnerabilities of uveal melanoma to develop novel therapeutic strategies. Chandrani Chattopadhyay. UT MD Anderson Cancer Center, Houston, TX, United States.

C31 Analysis of glycolytic energy metabolism in three dimensional cultured pancreatic cancer cell lines. Chikako Yokoyama. Osaka Metropolitan University, Osaka, Japan.

C32 Development of an AI Model for Predicting Pancreatic Cancer Based on Urinary Metabolomics Analysis. Taisuke Baba. Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.

C33 Diet alters NAMPT-targeting of lung and prostate neuroendocrine carcinoma (NEC). Nobuhiro Tanuma. Miyagi Cancer Center Reserch Institute, Natori, Japan.

C34 B3-AR ANTAGONIST SR59230A REPROGRAMS LIPID METABOLISM IN T-ALL AND FLT3-MUTATED AML BY TARGETING CD36: A NOVEL THERAPEUTIC STRATEGY. Cristina Banella. AOU Meyer IRCCS, Florence, Italy.

C35 Roles of estrogen-related receptor, PGC-1alpha and mitochondrial respiratory supercomplex assembly factor COX7RP in prostate cancer. Satoshi Inoue. Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan.

C36 OXPHOS as a driver of treatment resistance in non-small cell lung cancer: From computational analysis to preclinical modeling. Martin Benej. The Ohio State University, Columbus, OH, United States.

C37 Diet-induced microbiome alterations accelerate head and neck squamous cell carcinoma progression in murine models. Anastasia E. Abello. University of California, Davis, Sacramento, CA, United States.

13th AACR-JCA Joint Conference
From Cancer Discovery Science
to Therapeutic Innovation
February 1-5, 2025 | Maui, HI

AACR American Association for Cancer Research

JCA 一般社団法人 日本癌学会 JAPANESE CANCER ASSOCIATION

2409026E

C38 Kupffer cell polarization and glycolysis activation in MASH progression and oncogenesis. Yosuke Inomata. Osaka Medical and Pharmaceutical University, Takatsuki, Japan.

C39 Systemic physiological changes indicative of cancer cachexia. Venise Jan Castillon. Memorial Sloan Kettering Cancer Center, New York City, NY, United States.

C40 Genome-wide CRISPR screen identifies squalene epoxidase as a fluvastatin sensitizer to effectively target the mevalonate pathway in breast cancer. Linda Z. Penn. Princess Margaret Cancer Centre, Toronto, ON, Canada.

C41 Generation and characterization of a novel genetic model of mitochondrially driven hypoxia in NSCLC. Katarina Benejova. The Ohio State University, Columbus, OH, United States.

C42 Comparison of Outcomes Between Gene-Matched and Non-Gene-Matched Therapies in Solid Cancer Patients Using Integrated Clinical and Genomic Data. Taisuke Ishii. Institute of Cancer Control, National Cancer Center, Tokyo, Japan.